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Abstract
Background: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. Phloretin (PH)
possesses anticancer, antitumor, and hepatoprotective effects, however, the effects and potential mechanisms of
phloretin remain elusive.
Methods: Five HCC cells were tested in vitro for sensitivity to PH, Sorafenib (Sor) or both and the apoptosis, signal
transduction and phosphatase activity were analyzed. To validate the role of SHP-1, we used PTP inhibitor III and
SHP-1 siRNA. Further, we used purified SHP-1 proteins or HCC cells expressing deletion N-SH2 domain or D61A
point mutants to study the PH efficacy on SHP-1. The `in vivo studies were conducted using HepG2 and SK-Hep1
and Sor resistant HepG2SR and Huh7SR xenografts. Molecular docking was done with Swiss dock and Auto Dock
Vina.
Results: PH inhibited cell growth and induced apoptosis in all HCC cells by upregulating SHP-1 expression and
downregulating STAT3 expression and further inhibited pAKT/pERK signaling. PH activated SHP-1 by disruption of
autoinhibition of SHP-1, leading to reduced p-STAT3Tyr705 level. PH induced apoptosis in two Sor-resistant cell lines
and overcome STAT3, AKT, MAPK and VEGFR2 dependent Sor resistance in HCCs. PH potently inhibited tumor
growth in both Sor-sensitive and Sor-resistant xenografts in vivo by impairing angiogenesis, cell proliferation and
inducing apoptosis via targeting the SHP-1/STAT3 signaling pathway.
Conclusion: Our data suggest that PH inhibits STAT3 activity in Sor-sensitive and -resistant HCCs via SHP-1–
mediated inhibition of STAT3 and AKT/mTOR/JAK2/VEGFR2 pathway. Our results clearly indicate that PH may be a
potent reagent for hepatocellular carcinoma and a noveltargeted therapy for further clinical investigations.
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Background
Hepatocellular carcinoma (HCC) is the fifth leading cause
of cancer death worldwide accounting for 9.1% deaths [1].
Sorafenib (Sor, Fig. 1a), a tyrosine kinase inhibitor, is the
first and only targeted drug approved for use in HCC [2].
Although, it prolongs the median survival time with lim-
ited side effects in HCC patients, many patients become
resistant to Sor, which is the bottleneck in extending the
overall survival time for HCC patients [3]. Signal Trans-
ducer and Activator of Transcription 3 (STAT3) repre-
sents a key transducer in signaling pathways involved in
the injury-inflammation-regeneration response associated
with chronic liver diseases and human HCC development
[4, 5]. STAT3 is considered as a major target by Sor [4, 5],
in which increased STAT3 activity is related to the poor
diagnosis, severe drug resistance and declining survival
period in patients [6].
The Src homology region 2 domain-containing
phosphatase-1 (SHP-1) plays a crucial role in glucose
homeostasis and lipid metabolism in the liver [7, 8]. SHP-1
is one of the protein tyrosine phosphatase (PTP) members
that could suppress STAT3 pathway [9] and dephosphory-
late JAK kinases [10] and STAT3 directly [11]. SHP-1 has
been shown to function as a tumor suppressor to inhibit
the tumor growth [12, 13]. Certain target drugs such as
dovitinib and SC-2001 are known to induce apoptosis, au-
tophagy, and HCC cell growth inhibition through enhan-
cing the activity of SHP-1 tyrosine phosphatase in HCC
[14, 15]. Various STAT3 inhibitors have been designated to
directly target STAT3 mainly by inhibiting its dimerization,
DNA binding, or nuclear translocation [16, 17]. However,
only few of these inhibitors have demonstrated a significant
blockade of STAT3 functions. Thus, identifying effective
STAT3 inhibitor molecules that could revert the Sor resist-
ance to develop individualized therapeutic strategies for
clinical application in cancer is a need.
Among these promising molecules is Phloretin (PH).
PH is a dihydrochalcone flavonoid (C15 H14 O5, Fig. 1b)
Fig. 1 PH inhibits cell proliferation and induces apoptosis in HCCs. a Sor and (b) PH structure. c Cell viability by MTT assay. d DNA fragmentation
assay. e Apoptosis was analyzed by annexin V, FACS analysis. Annexin V (+) cells were quantified. f The protein levels of caspase-3 and PARP were
determined by Western blot after exposing HCCs to PH for 48 h. Experiments were conducted in triplicate and mean values ± SD (bars) are
shown. *p < 0.05, and **p < 0.01 compared to control
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that is mainly found in fruit, leaves, and roots of apple
tree. In general, PH has high safety margin with less side
effects. Several previous in vitro and in vivo studies
showed that PH is not toxic to several non-cancerous
cells such as epithelial breast cells MCF10A [18] and
normal human dermal fibroblast [19]. It has also been
reported that PH scavenges ONOO- and inhibits lipid
peroxidation in rat liver microsomes [20]. Furthermore,
pre- and post-treatment with PH significantly protected
the liver from acetaminophen- and carbon tetrachloride
(CCl4)-induced hepatotoxicity and reduced the degree
of liver damage [20, 21]. Importantly, PH is shown to ex-
hibit anticancer [22, 23], antitumor [24], and hepatopro-
tective effects with little side effects [25]. However, the
exact mechanism of the antitumor effects of PH in HCC
remains uninvestigated. Therefore, the main objectives
of the current work were to a) explore the molecular
mechanism(s) by which PH inhibits HCC proliferation
in vitro and in vivo models and b) assess the role of PH
in Sor-resistant xenografts. The results of the current
work clearly showed that PH exhibited anticancer poten-
tial in vitro and retarded tumor growth via targeting the
SHP-1/STAT3 and AKT/VEGFR2 signaling pathway.
Methods
PH and Sor were purchased from Sigma-Aldrich (USA) and
Selleck Chemicals LLC (Houston, TX). The SHP-1 inhibitor
and PTP inhibitor III (CAS 29936-81-0) were purchased
from Cayman Chemical (Ann Arbor, MI, USA). Smart-pool
siRNA, including control (D-001810-10), SHP-1 (PTPN6)
were all obtained from Dharmacon Inc. (Chicago, IL). The
mutant SHP-1 constructs (DN1 and D61A) have been gener-
ated to mimic the open-form structure of SHP-1 as previ-
ously described [11]. Antibodies for immunoblotting such as
p-STAT3, STAT3, survivin, p-Akt, Akt, p44/42 MAPK
(Erk1/2) (Thr202/Tyr204), ERK, p-VEGFR2, VEGFR2, p-
mTOR, mTOR, p-JAK2, JAK2, poly (ADP-ribose) polymer-
ase (PARP) and cleaved caspase 3 were ordered from Cell
Signaling Technology (Danvers, MA, USA). SHP-1, cyclin
D1, Mcl-1, Ki67, b-actin antibodies were purchased from
Abcam (Cambridge, MA, USA). BCA Protein Assay Kit was
purchased from Pierce (Rockford, IL, USA).
Cell Culture
Human hepatocellular carcinoma cells HepG2, SK-Hep1,
Hep3B2.1-7, Huh-7, and PLC-5 were obtained from the
American Type Culture Collection (Manassas, VA) and
cultured in Dulbecco’s Modified Eagle's Medium (DMEM;
GIBCO, MD, USA), containing 10% (v/v) fetal bovine
serum (FBS; GIBCO, MD, USA) at 37 °C in a 5% CO2- hu-
midified incubator. All cell lines were authenticated by
STR profiling using the AmpFISTR Identifiler PCR ampli-
fication kit (Applied Biosystems, Foster City, CA).
Establishment of Sor-resistant cells
Sorafenib-resistant cells HepG2SR and Huh7SR were estab-
lished as described [26]. In brief, two Sor-resistant HCC cell
lines (HepG2SR and Huh7SR) were obtained by chronic
exposure to Sor at low doses then increased to higher doses
for a long period of time. Their ability of Sor resistance (SR)
was further established and confirmed by incubating them
with Sor at a starting concentration of 5 μM. Cells were
continuously cultured with increasing concentrations of
Sor by 1 μM per week for 1–2 months. The re-obtained
SR-HCC cells were kept by culturing them in the presence
of Sor.
Patient samples
All pathologic samples of patients were obtained follow-
ing written informed consent. The protocol conforms to
the ethical guidelines of the 1975 Declaration of Helsinki
as reflected in a priori approval by the institution's
human research committee.
Cell proliferation analysis
Cells were seeded in 96-well plate with 5,000 cells per
well and were then treated with PH and/or Sor at indi-
cated concentrations for 24, 48 and 72 h. After 24 h of
incubation, 20 μl MTT (5 mg/ml) was added. The cul-
tures were solubilized and the spectrophotometric ab-
sorbance was measured at 595 nm using a microtiter
plate reader (Bio-Rad, USA). The number of viable cells
was presented relative to untreated controls. The assay
was repeated three times independently.
Colony formation assay
Colony formation assay was conducted as described
previously [14]. Briefly, HepG2SR and Huh7SR cells were
seeded in 6-well plates (~1000-5000 cells per well) and
treated with PH (50 μM). After incubation for 48 h, the
cells were washed by PBS and then cultured in normal
medium for two weeks. At the end of time point, cells
were washed in PBS, fixed with 100% methanol and
stained with a filtered solution of crystal violet (5% w/v).
Colonies were visualized by Nikon Eclipse TS100 inverse
microscope (Nikon Corporation, Japan) and pictures
were captured using Nikon E8400 camera.
DNA fragmentation
Cytoplasmic histone-associated DNA fragments were de-
termined by the measurement of apoptotic cells using the
Cell Death Detection ELISAPLUS Kit Roche (Indianapolis,
IN) according to the manufacturer's instructions.
Apoptosis assay
Approximately 2×105 cells/well seeded in 6-well plates
were treated with varying concentrations of PH for 48 h.
Thereafter, the cells were collected and washed twice in
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ice-cold PBS before incubated with 5 μL FITC-Annexin
V and 5 μL propidium iodide (PI) at room temperature
for 15 min in the dark. Apoptotic cells were detected
using an Annexin V-FITC Kit (BD Pharmingen, Franklin
Lakes, NJ, USA) according to the manufacturer’s proto-
col. All samples were analyzed immediately using
FACSCalibur flow cytometer (BD, San Jose, CA).
Measurement of caspase-3, -8 and -9 activities
Caspase-3, -8 and -9 colorimetric Assay kits (BioVision,
Inc.) were utilized as an additional method to evaluate
apoptosis. The results are expressed as relative caspase-3,
-8 and -9 activation in cells exposed to PH or Sor or both.
HCC with ectopic STAT3 expression
STAT3 cDNA (KIAA1524) was purchased from Addgene
plasmid repository (http://www.addgene.org). HepG2 and
SK-Hep1 cells with ectopic expression of STAT3 derived
from a single stable clone were exposed to PH. Briefly,
following transfection, cells were cultured in the presence
of G418 [27]. After eight weeks of selection, surviving
colonies arising from stably transfected cells were selected
and individually amplified.
Gene knockdown using siRNA
siRNAs targeting STAT3 and AKT with scrambled con-
trol siRNAs were purchased from Dharmacon (Thermo
Scientific, Chicago, IL, USA). Cells were transfected with
siRNAs using Lipofectamine 2000 (Invitrogen Life Tech-
nologies, MD, USA) to knockdown gene expression as
described previously [26].
SHP-1 Phosphatase activity
SHP-1 activity was determined by using a RediPlate™ 96
Enzchek™ Tyrosine Phosphatase Assay Kit (Thermo Scien-
tific, Chicago, IL, USA) according to the manufacturer's
instructions.
Phospho-STAT3 activity
Phospho-Stat3 (Tyr705) Sandwich ELISA Kit (Cell Signal-
ing Technologies) was used to measure p-STAT3 activity
according to the manufacturer's instructions.
Western Blotting
Cells or the isolated independent tissues were lysed with
RIPA Lysis Buffer (Santa Cruz Biotechnology, CA, USA)
containing protease inhibitor (Roche Corp., Basal, Swiss)
and phosphatase inhibitor (Roche Corp., Basal, Swiss) as
described previously [28]. The proteins were separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS–PAGE) and transferred to polyvinylidene difluoride
(PVDF) membranes. The membranes were then incubated
with primary antibodies overnight at 4°C followed by
secondary antibodies for 1h at room temperature. Protein
bands were visualized with enhanced chemiluminescence.
Real-time reverse transcription PCR
Total RNA was extracted from tumors using TRIzol
(Invitrogen) and RNeasy Mini Kit (Qiagen) and subse-
quently reverse-transcribed to cDNA using the SuperScript
Kit (Invitrogen). Quantitative PCR (qPCR) was carried out
on the MX3000P real-time PCR system (Stratagen, USA).
The amplification specificity was confirmed by the melting
curves. Relative mRNA levels were calculated based on the
Ct values and normalized using β-actin expression, accord-
ing to the equation: 2−ΔCt [ΔCt = Ct target gene-Ct β-actin]. All
experiments were performed in triplicate.
Tumor xenografts
To investigate whether PH has a therapeutic effect on
tumorigenesis in vivo, HepG2 (2 × 106) and SK-Hep1 (3 ×
106) cells were injected SC inoculated into the posterior
flank of nude mice and treated IP with PH 5 times a week
for 3 weeks. Further to extrapolate our in vitro results
to in vivo, we injected HepG2SR (3 × 106) and Huh7SR (5 ×
106) cells in mice which received daily oral Sor at 10mg/kg,
which was used to maintain the Sor-resistant capacity of
both HepG2SR and Huh7SR cells in mice [29]. When tumors
became palpable ~100mm3, animals were randomly divided
and received PH, Sor or both. Tumor volume (TV) was
calculated as follows: TV = (L × W2)/2 every third day till
the animals were sacrificed and tumor weights were mea-
sured on day 30 after tumor excision. Survival rate was eval-
uated by the Kaplan–Meier method. Mice of each group
were also monitored for other symptoms of side effects in-
cluding food and water withdrawal and impaired posture or
movement. At the termination of the experiment, the tumor
tissues were harvested and used for immunohistochemistry.
All procedures for animal experimentation used in the
current study were approved by the Institutional Animal
Ethics Committee, King Saud University, Riyadh, Saudi
Arabia.
Immunohistochemical staining
In brief, 5 μm-thick paraffin-embedded tumor sections from
nude mice were stained for CD31, pSTAT3, Caspase-3,
TUNEL and Ki67 using standard immunostaining protocols
[30] and scanned at ×200 magnification. Six fields per
section were analyzed and the expression levels of the target
markers were semi-quantitatively assessed based on staining
intensity by a board-certified pathologist.
Molecular docking with SHP-1
SHP-1 was downloaded from RCSB PDB using pdb id:
3PS5. The protein was first prepared and the active sites
were predicted using Discovery studio. his protein was then
used for docking purpose using Autdock Vina [31–33].
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Further, PH was docked with AKT1(4EJN). Each crystal
structure of mentioned proteins was co-crystallized with a
ligand bound at ATP binding site. Centre of mass of each
bound ligand was calculated and utilized during molecular
docking simulation. AutoDock vina program [31–33] was
used for molecular docking and calculating the binding
score of bound ligands of the proteins. Ligand efficacy (LE)
of PH and other ligands was calculated as described by
Hopkins et al [34]. UCSF Chimera and Ligplot programs
were used for visualizing, editing and analysis of ligand and
proteins interactions [35, 36].
Statistics
Statistical analysis was performed with GraphPad Prism
(GraphPad Software, San Diego, CA). Student’s t test
was used to evaluate statistical significance of differences
between two groups and p < 0.05 was considered statis-
tically significant. Measurement values were expressed
as mean ± SD.
Results
PH possesses anticancer and apoptotic effects in HCCs
and potentiates Sor efficacy
To investigate the anticancer effects of PH against hepatic
carcinoma, we first assessed growth inhibition in response
to PH, in a panel of five HCC cell lines: SK-Hep1,
Hep3B2.1-7, Huh7, PLC5, and one human hepatoblastoma
cell line HepG2. Cell viability was determined by MTT
assay after treatment for 24, 48 and 72 h. As shown in (Fig.
1c), PH significantly reduced cell viability in a concentra-
tion- and time-dependent manner. Next, we examined the
apoptotic effect of PH on HCCs. PH alone significantly in-
creased the activation of caspase-3, 8 and 9 in HepG2 and
SK-Hep-1 cells as observed with colorimetric assay (Bio Vi-
sion, USA) (Additional file 1: FigureS1A). Importantly, in-
hibition of cellular growth and activation of apoptosis by
PH were associated with a significant induction of DNA
fragmentation in a concentration-dependent manner in all
the five HCC cell lines (Fig. 1d). To further explore the
mechanism of cell death mediated by PH in HCCs, we first
measured the degree of cell apoptosis using Annexin V/PI
staining. PH alone increased the percentage of HCC cells
underwent apoptosis (Annexin V+/ PI+ population), a bio-
marker of apoptosis, in a concentration-dependent manner
(Fig. 1e). Second, we studied the effect of PH on caspase-3
cleavage, where we found that PH induced the activation of
caspase-3 cleavage and increased cleavage of poly (ADP- ri-
bose) polymerase in all HCC cell line tested (Fig. 1f).
To answer the question of whether PH could enhance the
cancer activity of Sor, we tested the effect of PH and Sor
combination on cell proliferation and apoptosis in several
HCC cells. Our results showed that Sor or PH alone de-
creased cell proliferation of HepG2, SK-Hep1, Hep3B2.1-7
cells in a concentration-dependent manner, whereas
combination of Sor and PH significantly potentiated the
suppression of the cell proliferation (Additional file 2: Figur-
eS2A), while significantly increased the apoptosis as ob-
served by Annexin V and DNA Fragmentation assays
(Additional file 2: Figure S2B, S2C). These data not only in-
dicate that PH inhibits HCC cell proliferation through in-
duction of apoptosis but also shed the light on its synergistic
effect on the antitumor activity of Sor.
To explore the role of STAT3 and SPH-1 in the antican-
cer activity of PH, two independent experiments were
conducted. First, we measured the effect of combination
therapy on p-STAT3 and SHP-1 activities. Our results
showed that PH in combination with Sor markedly de-
creased the p-STAT3 (Additional file 2: Figure S2D, S2E)
while enhanced SHP-1 (Additional file 2: Figure S2F)
activities as compared to monotherapy. Second, we next
examined whether knockdown of STAT3 and Akt by siR-
NAs could potentiate the anticancer activities of PH in
HCC cells. For this purpose, HepG2 and SK-Hep1 cells
were transfected with control, STAT3 siRNA or Akt
siRNA for 24 h and then further combined for 48 h with
PH (Additional file 3: Figure S3A, S3B). Our results show
that knockdown of both STAT3 and Akt by siRNA in-
duced apoptosis in both cells, suggesting that PH inhibits
Sor-induced STAT3 and Akt activation, thus reversing
Sor resistance in HCCs.
PH induced HCC cell death via inhibiting STAT3/AKT/ERK
signaling
In order to study the function of signal transduction cas-
cade in hepatocarcinogenesis, we investigated the effect
of PH on the phosphorylation of STAT3, MAPK and the
expression of Akt and JAK2 proteins. The results illus-
trated in Fig. 2a shows that PH significantly inhibited
STAT3 protein phosphorylation at tyrosine 705 transac-
tivation of STAT3 and its downstream pro-proliferative
proteins Mcl-1, cyclin D1 Bcl-xl and Survivin in a
concentration-dependent manner. Furthermore, al-
though PH did not affect the total STAT3 activity levels,
it significantly inhibited p-STAT3 activity levels in a
concentration-dependent manner (Fig. 2b) and its protein
expression in both the cytoplasm and nucleus (Fig. 2c). In
addition, PH downregulated the expression of p-Akt, p-
ERK, p-mTOR, p-VEGFR2 and p-JNK in a concentration-
dependent manner without having effect on the total ex-
pression of these proteins (Fig. 2a).
To further validate the role of STAT3 in PH-
induced apoptosis, we generated stable STAT3-
overexpressing HepG2 and SK-Hep1 and tested the
molecular changes induced by PH treatment. Ectopic
expression of STAT3 increased p-STAT3 protein ex-
pression (Fig. 2d) and decreased the percentage of
apoptotic cells (Fig. 2d), suggesting that activated
STAT3 signaling counteracts the apoptotic activity of
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Fig. 2 (See legend on next page.)
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PH in HCCs. To tested whether these in vitro results
are extrapolated into human model, we performed
immunohistochemistry (IHC) assay to examine the
levels of CD31, SHP1 and pSTAT3 in liver tissues ob-
tained from healthy and HCC patients. IHC staining
shows strong SHP-1 correlation with p-STAT3 ex-
pression in normal liver and vice versa in human
tumor samples (Fig. 2e).
PH increased SHP-1 phosphatase activity by direct
interaction
SHP-1 activity has a critical role in induction of apop-
tosis in different cancer types [11–15]. To test whether
SHP-1 is involved in PH-induced STAT3 suppression,
we first tested the effect of PH on SHP-1 phosphatase
activity. PH alone significantly enhanced the phosphat-
ase activity of SHP-1 in a concentration-dependent man-
ner in all tested HCC cell lines (Fig. 3a). Thereafter, we
studied the effect of PH on SHP-1–containing cell lysates.
In brief, HepG2, SK-Hep-1 and Hep3B2.1-7 cells were
immunoprecipitated with anti-SHP-1 antibody, then
the protein extracts containing SHP-1 complex was further
incubated with different PH concentrations for 30 min be-
fore SHP-1 activity was determined. As shown in Fig. 3b,
PH (50 μM) significantly increased the phosphatase
activity of SHP-1–containing lysates in HepG2, SK-
Hep-1 and Hep 3B2.1-7 by approximately 7.89, 6.91
and 9.78-fold, respectively. For more specific identifi-
cation, we incubated pure SHP-1 recombinant protein
for 30 min with increasing concentrations of PH (25-
100 μM) followed by measurement of the SHP-1
phosphatase activity. Our results showed that PH (50
μM) treatment increased the SHP-1 phosphatase ac-
tivity in HepG2, SK-Hep1and Hep3B2.1-7 cells by ap-
proximately 4.5-, 3.5- and 5.8-fold, respectively,
suggesting that PH potentially acts on SHP-1 by dir-
ect interaction (Fig. 3c).
To further validate the role of SHP-1 in PH-mediated
molecular events and apoptosis, we tested whether inhib-
ition of SHP-1 either chemically using a specific inhibitor
(PTP III) or genetically via transient transfection of SHP-1-
targeted siRNAs would alter PH effects in HCC cells. Our
results showed that blocking of SHP-1 either using PTP III
(Fig. 3d) or siRNA (Fig. 3e) abolished PH-mediated cell
death and downregulation of p-STAT3 in both HepG2 and
SK-Hep1 cells. PH induced significant cell death and
inhibition of STAT3 in HepG2, SK-Hep-1 and Hep3B2.1-7
cells overexpressing SHP-1 (Fig. 3f). This data suggests that
PH increases SHP-1 activity by direct interaction that sub-
sequently results in SHP-1–mediated inhibition of p-
STAT3.
PH interfered with inhibitory N-SH2 domain and relieved
autoinhibition of SHP-1
To investigate the mechanism through which PH
increased SHP-1 tyrosine phosphatase activity, we
transfected HepG2 and SK-Hep1 cells with wild-type
or mutant SHP-1 (dN1 and D61A), thereafter we ex-
amined the effect of PH on SHP-1. The intramolecu-
lar inhibition of SHP-1 is protected by various
biochemical associations between N1 and PTP cata-
lytic domain, such as Asp61 and Lys362 (salt bridge)
[37]. Deletion of the autoinhibitory N-SH2 domain
(dN1) and single-mutant D61A of SHP-1 was used to
mimic the open-form structure of SHP-1. PH co-
incubated with purified wild-type or mutant SHP-1
proteins in vitro enhanced the activity of wild-type
SHP-1 protein to nearly 2.6 and 2-folds in HepG2
and SK-Hep1 cells, respectively (Fig. 3g). As com-
pared to Sor, sc-43 and sc-60, PH increased the phos-
phatase activity in recombinant SHP-1 proteins
expressing dN1 or D61A mutants in both HepG2 and
SK- Hep1 cells. In addition, wild-type SHP-1–transfected
HCC cells showed a marked decrease in p-STAT3Tyr705
level (Fig. 3i) and a significant increase in apoptosis (Fig.
3h, Additional file 2: Figure S2G). Whereas no such effect
was observed in dN1 or D61A mutant SHP-1–transfected
HCCs (Fig. 3i). These findings suggest that PH activates
SHP-1 by disruption of autoinhibition of SHP-1, leading
to reduced p-STAT3Tyr705 level and eventual induction of
apoptosis in HCC cells (Fig. 3j). Thus, SHP-1 targeting is
critical in PH-induced anti-HCC activity.
PH overcome Sor resistance in HCCs
Sor-resistant cell lines HepG2SR and Huh7SR were used
to study whether PH could overcome the resistance in
HCC cell lines and whether p-STAT3 and SHP-1 are in-
volved. Resistance of HepG2SR and Huh7SR cells to Sor
has been confirmed by the significant decrease in growth
inhibition (Additional file 4: Figure S4A), no significant
changes on p-STAT3 protein expression and percentage
of apoptotic cells (Additional file 4: Figure S4B), no
(See figure on previous page.)
Fig. 2 PH inhibits STAT3, AKT/mTOR and RAS/MAPK signaling in HCCs. a Cells were treated for 48h with indicated concentrations of PH and
phosphorylated and total protein levels of the target proteins were evaluated by Western blotting. b pSTAT-3 activity was measured by ELISA (c)
PH inhibits cytoplasmic, nuclear STAT3 phosphorylation in HCCs at 50uM. d Cells (wild-type or ectopic expression of STAT3) were exposed to PH
at 50uM for 24 hours. Percentage of apoptotic cells was analyzed by flow cytometry. e Representative images from two patients with double
immunostaing of CD31/SHP1 and pSTAT3. Experiments were conducted in triplicate and mean values ± SD (bars) are shown. *p<0.05, and **p<
0.01 compared to control
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Fig. 3 (See legend on next page.)
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induction of DNA fragmentation in both resistant cells
(Additional file 4: Figure S4C). These results clearly sug-
gest that Sor-resistant cells become refractory to Sor-
induced apoptosis.
We next explored the effect of PH in Sor-resistant
cells. The results illustrated in Fig. 4 shows that PH
attenuated cell growth of both HepG2SR and Huh7SR
cells (Fig. 4a) and induced DNA fragmentation in
both cells (Fig. 4b). This was further supported by
the ability of PH to significantly inhibit cell growth as
measured by colonogenic assay (Additional file 4:
Figure S4D) and by increased the protein expressions
of apoptotic genes, such as cleaved caspase-3, -9 and
PARP (Fig. 4c). Taken together, these results suggest
that PH has potent inhibitory effect on Sor-resistance
HCCs.
PH overcome STAT3-, AKT-, MAPK- and VEGFR2-
dependent resistance to Sor in HCCs
To further explore the mechanisms of PH effect on
Sor-resistant HCC cells, we investigated the effect of
PH on the protein expression and activity of p-
STAT3 and SHP-1 in Sor-resistant HepG2SR and
Huh7SR cells. PH treatment resulted in downregula-
tion of p-STAT3 protein expression and its targets
in a concentration-dependent manner (Fig. 4d) with
significant decrease in p-STAT3 activity at 50 and
100 μM concentrations using ELISA (Fig. 4e). With
regards to SHP-1, PH treatment caused marked
increases in SHP-1 activitiy (Fig. 4f) and mRNA (Fig.
4g) levels in both HepG2SR and Huh7SR cells.
STAT3 has been reported to be activated by JAK2
[38], therefore, we test the effect of PH on JAK2. Our
results showed that PH inhibited phosphorylation of
JAK2 in a concentration-dependent manner in Sor-
resistant cells (Fig. 4d). Previous study has shown that
Sor-induced Akt, ERK and VEGFR2 activation has
been reported in both Sor-resistant and parental HCC
cells [3, 4, 11] and that increased p-Akt, p-ERK and
p-VEGFR2 expression is responsible for resistance to
Sor. We next examined alterations of the key mole-
cules in the Akt/mTOR, MAPK and VEGFR2
pathways, pathways that have been shown to be re-
sponsible for resistance to Sor [11]. Our results
showed that Sor-resistant cells expressed higher levels
of p- Akt, p-ERK and p-VEGFR2 resulting in upregu-
lation of p-mTOR (Fig. 4d). Importantly, PH treat-
ment downregulated p-Akt, p-ERK, p-VEGFR2 and p-
mTOR protein expression in a concentration-
dependent manner but did not affect the total pro-
tein expression (Fig. 4d).
To further investigate the mechanism through
which PH increased SHP-1 and decreased p-STAT3
in Sor-resistant cells, we knocked down SHP-1 using
siRNA to address whether SHP-1 is mediating Sor re-
sistance. As shown in Fig. 4h, while PH treatment in-
creased SHP-1 and repressed p-STAT3 proteins with
inhibition of colony formation, SHP-1 silencing abol-
ished the inhibitory effects of PH on p-STAT3 and
colony formation in Sor-resistant cells. These results
not only indicate the critical role of SHP-1 in PH-
induced inhibition of cell growth, but also suggest
that targeting SHP-1 by PH could overcome Sor
resistance.
PH combination with Sor synergizes the antitumor effect
in SR-HCCs
To know whether PH could potentiate the antitumor
efficacy of Sor, we studied the combined effect of PH
and Sor in Sor-resistant HepG2SR and Huh7SR cells.
Combined therapy resulted in significant downregulation
of p-STAT3 and its downstream signal proteins in both
Sor-resistant cell lines (Fig. 5a). We further determined
the effect of combination therapy on SHP-1 and p-STAT3
activity in target gene regulation. Fig. 5b shows that PH
alone increased SHP-1 activity, while further potentiated
SHP-1 activity in the presence of Sor. In addition, combin-
ation therapy further downregulated p-STAT3 activity
(Fig. 5c), further inhibited colony forming ability in both
Sor-resistant cells (Fig. 5d), and significantly increased
cleaved caspase-3 and 9 proteins (Fig. 5e) and DNA Frag-
mentation (Fig. 5f). Taken together, these results strongly
suggest that PH potentiates the antitumor efficacy Sor.
PH inhibited tumor growth via a SHP-1/STAT3-related
signaling pathway in vivo
To investigate whether PH has anti-tumorigenic effect
in vivo, we subcutaneously injected HepG2 (2 × 106)
and SK-Hep1 (3 × 106) cells into the posterior flank
of nude mice followed by IP injection of PH at
(See figure on previous page.)
Fig. 3 PH enhances SHP-1 tyrosine phosphatase activity. a SHP-1 phosphatase activity. b The SHP-1-containing lysates of HCCs were collected by
SHP-1 antibody and incubated with PH for 30 min. c PH enhanced SHP-1 activity in cell-free SHP-1 protein. d HCCcells were pre-treated with 25
μM specific SHP-1 inhibitor (PTPIII) for 30 min and then co-incubated with PH 50 μM for additional 48 h. e Knockdown of SHP-1 reversed the
biological effects of PH on p-STAT3 and apoptosis. f PH reinforced apoptosis in stably expressing SHP-1 HCCs. g Purified dN1 and D61A mutants
of SHP-1 were insensitive to PH treatment. h Percentage of apoptotic cells was analyzed by flow cytometry. i Effect of dN1 and D61A mutants on
STAT3 expression. j Molecular model of PH. Experiments were conducted in triplicate and mean values ± SD (bars) are shown. *p < 0.05, and **p
< 0.01 compared to control
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indicated doses (25, 50, and 100 mg/kg) 5 times a
week for 3 weeks. Tumor growth was measured every
6 days till the animals were sacrificed on the 30th
day. Our results showed that PH decreased tumor
volume (Fig. 6a) and tumor weight (Fig. 6b) in both
HepG2 and SK-Hep1 xenografts in a dose-dependent
manner. Maximal efficacy was demonstrated with
both 50 and 100 mg/kg dose of PH. To further
understand the underlying mechanism in close prox-
imity of hepatic cancer, we analyzed the levels of p-
STAT3 protein expression and phosphatase activity of
SHP-1. PH treatment significantly increased the SHP-
1 tyrosine phosphatase activity (Fig. 6c), whereas
inhibited the expression of p-STAT3Tyr705 and its
downstream signaling targets (Mcl-1, survivin, Bcl-xl)
both at the protein (Fig. 6d), and mRNA (Fig. 6e)
Fig. 5 PH potentiates the effect of Sor in HepG2SR and Huh7SR cells in vitro. a Effect of PH (50 μM), Sor (10 μM) or both on p-STAT3 and its
downstream proteins in SR-HCCs. b SHP-1 phosphatase activity in SR-HCCs exposed to PH, Sor or both for 48 h. c pSTAT3 activity was measured
by ELISA. d Colony formation assay. e The protein levels of cleaved caspase-3 and -9 were determined by Western blot assay (f) DNA
fragmentation assay for cells exposed to PH, Sor or both for 48 h. Experiments were conducted in triplicate and mean values ± SD (bars) are
shown. *p < 0.05, and **p < 0.01 compared to control
(See figure on previous page.)
Fig. 4 PH overcomes Sor resistance in HepG2SR and Huh7SR cells in vitro. a PH inhibited cell growth in Sor resistant HepG2SR and Huh7SR cells. Cell
viability was assessed by MTT assay. b PH enhanced DNA fragmentation in SR-HCCs. c The protein levels of caspase-3, caspase-9 and PARP after
exposing SR-HCCs to PH. d PH inhibited STAT3, ERK, AKT/mTOR signaling in HCC cells. e pSTAT-3 activity was measured by ELISA. f SHP-1 phosphatase
activity in HepG2SR and Huh7SR. g SHP-1 mRNA levels were analyzed by qPCR. h SR-HCC cells were transfected with control siRNA or SHP-1 siRNA for
48 h there exposed to PH and subjected to Western blot assay of p-STAT3 and SHP-1 or seeded on a 6-well plate for the colony forming assay.
Experiments were conducted in triplicate and mean values ± SD (bars) are shown. *p < 0.05, and **p < 0.01 compared to control
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levels. All together, these effects were associated with
significant survival benefits by PH compared with
mice treated with vehicle in both HepG2 and SK-
Hep1 xenograft (Fig. 6f). The results of the in vivo
study suggest that suppression of tumorigenicity by
PH in vivo is due to its enhancement of SHP-1 activ-
ity that directly targeted p-STAT3Tyr705 expression.
Angiogenesis plays important role in tumor growth,
progression and metastasis [39]. Therefore, we
examined whether PH inhibits angiogenesis in vivo.
Immunostaining with CD31 markedly decreased angio-
genesis in tumor tissues in both HepG2 (Fig. 6g) and
SK-Hep1 (Additional file 5: Figure S5A) xenografts
treated with PH in a dose-dependent manner. Signifi-
cant decrease in p-STAT3 expression in both HepG2
(Fig. 6g) and SK-Hep1 (Additional file 5: Figure S5F)
xenografts was observed. TUNEL labelling and
caspase-3 expression revealed a high induction of
apoptosis by a factor of 9 and 10 in HepG2 (Fig. 6g)
and 8 and 11 in SK-Hep1 (Additional file 5: Figure
S5F) with PH 50 mg/kg. There was a significant de-
crease in Ki67+ cells in PH treated tumors (Fig. 6g;
Additional file 5: Figure S5F). These results suggest
that PH inhibits tumor growth by impairing angiogen-
esis, cell proliferation and inducing apoptosis in both
HepG2 and SK-Hep1 tumors.
Further, we tested the combined effect of PH and
Sor on the tumor volume in both HepG2 and SK-
Hep1 xenografts. PH (50 mg/kg) alone decreased the
tumor volume by 75% and 71%, whereas Sor alone
(20 mg/kg) decreased the tumor volume by 54% and
51% in HepG2 and SK-Hep1 xenografts, respectively
(Additional file 5: Figure S5A). Importantly, combin-
ation therapy of PH and Sor produced an additive
decrease in tumor volume by 83% and 89% in both
cells, respectively (Additional file 5: Figure S5A).
However, no significant changes in body weight loss
or other clinical signs of toxicity were observed in
any groups (Additional file 5: Figure S5B). Further
we examined whether the potentiation effect of com-
bined therapy of PH and Sor on tumor volume is as-
sociated with synergistic effect on SHP-1 and p-
STAT3. Additional file 5: Figure S5D shows that a
synergistic increase in SHP-1 activity with a further
decrease in p-STAT3 activity and downstream pro-
teins as compared to monotherapy. No histological
differences were observed in various organs between
the control and PH treated groups (Additional file 5:
Figure S5C). These results suggest that PH acts as a
potent STAT3 inhibitor and SHP-1 enhancer, and
thus induces its anti–hepatocellular carcinoma effect
via a STAT3-related signaling pathway.
PH possessed antitumor effect against Sor-resistant
xenograft tumors
To assess the antitumor activity of PH against Sor-
resistant xenografts, we injected HepG2SR (3 × 106) and
Huh7SR cells (5 × 106) cells in mice which have received
daily oral Sor dose (10 mg/kg), a dose that is used to
maintain the Sor-resistant capacity of both HepG2SR and
Huh7SR cells in mice [15]. When tumors became palp-
able ~100mm3, animals were randomly divided in four
groups as follows: first group received only vehicle (con-
trol), second group received PH (50 mg/kg), third group
received Sor (20 mg/kg), fourth group received both PH
plus Sor. As demonstrated in Fig. 7, SR-HCC tumors
were shown to be resistant to Sor in vivo since there was
a slight decrease in tumor volume and weight as com-
pared to vehicle treated group. However, PH treatment
decreased tumor volume and weight by 73% and 68% in
HepG2SR and by 74% and 64% in Huh7SR cells. Treat-
ment of mice with combination therapy of PH plus Sor
produced additive effect by decreasing tumor volume by
83% and 88% in HepG2SR and 80% and 86% in Huh7SR
xenografts (Fig. 7a and b).
We further investigated the effect of PH, Sor or com-
bination treatment on SPH-1 and p-STAT3 expression
in HepG2SR and Huh7SR xenografts. In consistency with
the in vitro and in vivo results, Western blot assay
results showed a significant decrease in p-STAT3 pro-
tein expression and its downstream targets (Fig. 7c) and
an increase in SHP-1 activity (Fig. 7d). In addition,
immunostainings for CD31, p-STAT3, caspase-3 and
ki67 showed that Sor had a weak inhibitory effect on cell
proliferation with weak pro-apoptotic activity against
Sor-resistant tumors (Fig. 7e), whereas, PH significantly
decreased CD31, p-STAT3 and Ki67 expression while
induced caspase-3 activity in both HepG2SR and Huh7SR
xenografts. These Inhibitory effects were also observed
in combination with Sor but is not significant as com-
pared to PH alone. Together, our data indicate that PH
(See figure on previous page.)
Fig. 6 PH inhibits tumor growth via downregulating STAT3-related signaling pathway. a PH significantly inhibited tumor growth in HepG2 and
SK-Hep1 tumor-bearing mice. b Tumor weight. c The in vivo SHP-1 phosphatase activity. d The protein levels of p-STAT3 and its downstream
proteins were determined by Western blot assay. e STAT3 and related mRNA levels were analyzed by qPCR. f Kaplan–Meier plot showing animal
survival after treatment with PH at indicated doses (n = 8). g Immunohistochemical staining (Left panel) of CD31, pSTAT3, cleaved caspase-3, Ki67
and TUNEL in tumor xenografts. Magnification: ×200. Data represents mean values from five random fields per tumor section. Scale bar, 50 μm.
Mean values ± SD (bars) are shown. *p < 0.05, and **p < 0.01 compared to control
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inhibited the tumor growth both in vitro and in vivo
through a STAT3 inhibition mechanism involving SHP-1.
Molecular docking
We performed docking of these ligands with SHP-1 (pdb
id: 3PS5) individually, using Autodock Vina (Fig. 8a). PH
docks within the predicted active site (Ser 453 to Thr 460)
into the interface of N-SH2 and PTP domain and forms
3H-bonds within the active site with docking score of -6.5
(Fig. 8a). Sor docks in a region spanning from Asp 419 to
Ser 474 and forms 2H bonds with docking score of -7.9.
These results showed that PH is equally potential candi-
date as Sor. All molecules have bound at AKT1’s ATP
binding site, whose coulombic charge distribution surface
is positively charged around opening but hydrophobic in
deeper side (Fig. 8b, c). This charge distribution plays a
role in binding of molecules if they are physicochemical
complementary with interacting surface. The binding af-
finity and ligand efficiency scores of 0R4, an inhibitor of
AKT1 (PDB id: 4EJN) are -13.9kcal/mol and -0.32kcal/
mol respectively. The binding energy of PH is -7.7Kcal/
mol and its ligand efficiency is -0.39 kcal due to presence
of 20 heavy atoms only. This analysis shows that PH binds
more efficiently with than 0åR4.
Discussion
Over-expression and hyperactivation of STAT3 has
been reported in various human tumors. STAT3 and
MAPK play an important role in signal transduction
cascades, which take part in cellular physiological
growth, development, mitogenesis and differentiation,
and cellular malignant transformation [17]. One of
the novel strategies to prevent sustained STAT3 over-
expression in cancer cells is through the activation of
intrinsic regulators such as SHP-1 [40]. This effect is
supported by the findings of several studies revealed
that loss of SHP-1 leads to constitutive activation of
STAT3. In addition, SHP-1 has been shown to
Fig. 8 Molecular Docking. a PH shows 3 BS of protein with 3H-bond, Sor shows binding near to active site (with 2-H bond). b N-Sh2, C-Sh2, and
PTP domains of Shp1 protein (2B3O) structure. The four binding sites (BS) identified from Swiss dock models are marked in the imaged along
with the predicted binding affinities for Sor (SFB) and PH (PHL). c Docking of PH in ATP binding site of AKT1 protein (PDB id: 4EJN). PH and 0R4
are in rosy brown and sea green respectively (Left)
(See figure on previous page.)
Fig. 7 PH overcomes the Sor resistance in HepG2SR and Huh7SR xenografts in vivo. a PH significantly reduced tumor growth in SR-HCCs
xenografts. When tumors reached 100 mm3, the mice were treated with PH, Sor or both and then tumor growth was measured every 3 days. b
Tumor weight was measured on day 30 after tumor excision. c The protein levels of p-STAT3 and its downstream proteins were determined by
Western blot. d The in vivo SHP-1 phosphatase activity. e Immunohistochemical staining of CD31, p-STAT3, cleaved caspase-3, Ki67 and TUNEL in
HepG2SR and Huh7SR xenografts. Magnification: ×200. Data represents mean values from five random fields per tumor section. Scale bar, 50 μm.
Mean values ± SD (bars) are shown. *p < 0.05, and **p < 0.01 compared to control
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dephosphorylate STAT3 directly to silence the JAK/
STAT pathway [38]. The current study provides the
first evidence that PH demonstrates a significant anti-
proliferative effect in HCCs via STAT3 pathway in-
hibition. Our data suggest that PH inhibits the JAK/
STAT3 signaling pathway by stimulating Tyr705 de-
phosphorylation of STAT3 and inhibiting p-JAK2.
PH also upregulates SHP-1 activity and induces SHP-
1-dependent p-STAT3 downregulation.
Activation of the AKT/mTOR and RAS/MAPK cascades
is frequently observed and associated with aggressive tumor
phenotypes and poor prognosis in human HCC [39]. SHP-
1 is a negative regulator of the cell cycle, as well as inflam-
matory and JAK/STAT pathways in cancer progression
[41]. We have observed that PH significantly decreased ex-
pression of p-ERK p-Akt and p-mTOR in all tested HCCs.
Inhibiting SHP-1 using specific inhibitor, PTP inhibitor III,
upregulates p-STAT3 and rescues the SC-43-induced
apoptosis. The antiproliferative activity of PH was signifi-
cantly counteracted by SHP-1 knockdown using siRNA
suggesting that PH mainly targets SHP-1 and downregu-
lates p-STAT3, and thus inhibits cell proliferation and in-
duces apoptosis. The dN1 mutant showed slight increase in
SHP-1 activity in both HCCs, but it was not significant,
whereas D61A mutants demonstrated a significant increase
in SHP-1 activity only in HepG2 not in SK-Hep1 indicating
that D61 site of the inhibitory N-SH2 domain is crucial for
PH-induced SHP-1 upregulation, although it behaves dif-
ferently in HepG2 compared to SK-Hep1 cells. This could
be explained by its flexible orientation and unknown
mechanism for searching of phospho-tyrosine activators
[11]. PH-induced downregulation of p-STAT3 was found
in HCCs cells expressing wild-type (WT) of SHP-1. How-
ever, ectopic expression of dN1 and D61A restored the ex-
pression of p-STAT3. Together, the data suggest that PH
may affect SHP-1 by switching the confirmation from auto-
inhibitory (closed) to active (open). Our in vivo studies
recaptured our findings in vitro, that PH showed significant
antitumor activity via inhibition of p-STAT3 and upregula-
tion of SHP-1 activity in HCC- xenografts and improved
the overall survival.
Several mechanisms are involved in the acquired resist-
ance to Sor, such as crosstalk involving PI3K/Akt and JAK-
STAT pathways, the activation of hypoxia-inducible path-
ways and epithelial-mesenchymal transition [42, 43]. There-
fore, it is of great impact to develop individualized
therapeutic strategies for treatment of Sor resistance cases.
Since our current observations clearly show that PH acti-
vated SHP-1 and reduced the level of p-STAT3 activity and
expression in vitro and in vivo, we hypothesized that PH
overcomes STAT3-dependent Sor-resistance in HCC cells.
This hypothesis was evidenced in two Sor-resistant HCC
cell lines by which PH decreased cell viability, colony for-
mation and increased apoptosis. Sor-resistant HCC cells
express higher levels of pAkt, m-TOR, pERK, p-STAT3, p-
JAK2, but lower levels of SHP-1 and p-SHP-1, indicating
that the JAK-STAT pathway participates in the acquired re-
sistance to Sor in HCC. PH overcomes the Sor resistance
via downregulating the expression of pAkt, pERK, p-
STAT3, p-JAK2 along with decrease in pVEGFR2 in SR-
Fig. 9 Graphical abstract for the proposed mechanism of action of PH in HCC
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HCC. In addition, we confirmed the anticancer activity of
PH to overcome Sor resistance of HCC in experimental an-
imals. We inoculated SR-HCCs to animals and found that
PH significantly retarded the growth of tumors in SR-HCC
xenografts. We also found that PH used in combination
with Sor displayed synergistic effect in vitro in SR-HCC but
not in vivo tumors. To our knowledge, this is the first re-
port showing that PH inhibits HCC in vitro and in vivo via
targeting STAT3/SHP1signaling pathway. A proposed
mechanism of action of PH on Sor-resistant and -sensitive
HCC is illustrated in Fig. 9.
Conclusion
In summary, our study demonstrated the preclinical activ-
ity of PH, which inhibits hepatic carcinoma in vitro and
in vivo and prolonged mouse survival via molecular tar-
geting of STAT3/Akt/mTOR/JAK2/VEGF2 pathways. PH
holds promise as an adjuvant drug for HCC treatment
and is equally as potential as Sor. This may represent an
alternative strategy in the treatment of HCC.
Additional files
Additional file 1: Figure S1. Colorimetric assay of caspase-3, -8 and -9
activity in HepG2 and Sk-Hep1. (A) Cells were treated with PH or Sor or
both at indicated doses for 48 h and caspase-3, -8 and -9 activities were
measured by colorimetric kits from Abcam, Cambridge, MA, USA).
Experiments were conducted in triplicate and mean values ± SD (bars)
are shown. *p < 0.05, and **p < 0.01 versus control. (DOCX 161 kb)
Additional file 2: Figure S2. PH potentiates the effect of Sor in vitro in
HCCs. (A) HepG2, SK-Hep1 and Hep 3B2. 1-7 cells were treated with PH
or Sor or both at indicated doses for 48 h and growth inhibition was
assessed by MTT assay. (B) PH enhanced DNA fragmentation. PH or Sor
or both at indicated doses for 48 h and DNA fragmentation was
measured by cell death detection ELISA. (C) Apoptosis was analyzed by
annexin V labeling and FACS analysis. Annexin V (+) cells were quantified.
(D) pSTAT-3 activity was measured by ELISA. (E) The protein levels of p-
STAT3 was determined by western blot (F) HCC cells were exposed PH or
Sor or both at the indicated doses for 48 h and SHP- 1 phosphatase
activity was determined. (G) Purified dN1 and D61A mutants of SHP-1
were insensitive to PH treatment. (H) Percentage of apoptotic cells was
analyzed by flow cytometry in purified dN1 and D61A mutants of SHP-1
treated with PH. Experiments were conducted in triplicate and mean
values ± SD (bars) are shown. *p<0.05, and **p<0.01 versus control.
(DOCX 161 kb)
Additional file 3: Figure S3. Knockdown of STAT3 and Akt sensitizes
PH-induced apoptosis. (A) siRNA against STAT3 enhanced apoptosis in
HepG2 and SK-Hep1 cells. (B) siRNA against Akt enhanced apoptosis in
HepG2 and SK-Hep1 cells. Experiments were conducted in triplicate and
mean values ± SD (bars) are shown. *p<0.05, and **p<0.01 versus control.
(DOCX 71 kb)
Additional file 4: Figure S4. Sor-resistant HCC cells are insensitive to
Sor. (A) HepG2, HepG2-SR, Huh7 and Huh7-SR cells were incubated with
serial concentrations of Sor for 48 h. Cell growth inhibition was assessed
by MTT assay. (B) Cells were incubated with Sor (10uM) and analyzed for
apoptosis by FACS analysis. (C) The protein levels of p- STAT3 were
determined by Western blotting (D) Cells were exposed to PH at the
indicated concentrations for 48 h. DNA fragmentation was measured by
cell death detection ELISA. Experiments were conducted in triplicate and
mean values ± SD (bars) are shown. *p<0.05, and **p<0.01 versus control.
(DOCX 111 kb)
Additional file 5: Figure S5. PH potentiates the antitumor effect of Sor
in HepG2 and SK-Hep1 xenografts. (A) HepG2 and SK-Hep1 xenografts
were treated with PH (50mg/kg) or Sor (20mg/kg) or both and tumor
growth was measured every 6 days. (B) No significant change in
bodyweight was observed in treated groups (C) H and E images of heart,
lung, liver and spleen showing no toxic effect of with PH treatment. (D)
The in vivo SHP-1 phosphatase activity in PH (50 mg/kg) or Sor (20 mg/
kg) or both treated tumors. (E) The protein levels of p-STAT3 and its
downstream proteins in HepG2 and SK-Hep1 xenografts in vivo were
determined by western blot. (G) Immunohistochemical staining (Left
panel) of CD31, pSTAT-3, cleaved caspase-3, Ki67 and TUNEL in PH
treated SK-Hep1 xenografts. Magnification: ×200. Quantifications of
Immunostainings (Left Panel) Quantification of CD31+ vessel area per
total tumor area. Quantification of pSTAT-3, cleaved caspase-3, TUNEL
and Ki67 cells per high power field of view. Data represents mean values
from five random fields per tumor section. Scale bar, 50 μm. Experiments
were conducted in triplicate and mean values ± SD (bars) are shown.
*p<0.05, and **p<0.01 versus control. (DOCX 529 kb)
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